Synergy Pharma (SGYP) Tops Q4 EPS by 3c, Beats on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Synergy Pharma (SGYP) Tops Q4 EPS by 3c, Beats on Revenues

Cipher Acquires Canadian Rights to TRULANCE from Synergy (SGYP) for $5M Upfront

February 28, 2018 7:07 AM EST

Cipher Pharmaceuticals Inc. has acquired the exclusive Canadian rights to right to develop, market, distribute and sell TRULANCE from Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration ("FDA") for the treatment of adults with chronic idiopathic constipation ("CIC") and irritable bowel syndrome with constipation ("IBS-C").

"We are excited at the prospect of bringing an innovative new product to market that would be a safe and effective... More